普罗布考改善AMI患者PCI预后及炎症反应的临床研究

目的：研究使用普罗布考对急性心肌梗死（AMI）患者冠状动脉介入术（PCI）后预后及炎症反应的作用。方法：AMI患者82例,随机分为普罗布考组（41例）及对照组（41例）,两组患者均行冠状动脉造影及PCI治疗。普罗布考组在常规用药基础上加普罗布考500mg/次,每日2次。对照组应用辛伐他汀10mg每晚一次口服。记录所有患者住院期间及出院后30 d内心血管事件。并予以炎症相关生物标志物——肿瘤坏死因子（TNF-α）,CD40配体（CD40L）,P选择素（Ps）检测。结果：普罗布考组住院期间及出院后30 d累计发生心血管事件3例,与对照组相同（P〉0.05）。两组术前CD40L,Ps及TNF-α水平无统计学差异（P〉0.05）;出院后30 d CD40L,Ps及TNF-α各指标同术前比较均显著下降（P〈0.05）;普罗布考组出院后30d TNF-α,CD40L,Ps水平较与照组无明显差异（P〉0.05）。结论：普罗布考可减轻AMI行PCI治疗患者炎症反应,改善预后。

Probucol Improve Prognosis and Inflammation after Percutaneous Coronary Intervention in the Patients with Acute Myocardial Infarction

Objective ：To investigate the value of probucol at prognosis and inflammation after percutaneous coronary intervention （PCI） in the patients with acute myocardial infarction （AMI）. Methods：Eight-two patients with AMI were divided into probucol group （41patients） and control group（41patients） randomly. Probucol group was given Probuco1500mg Bid po; control group given Simvastatin 10mg Qd po. Cardiac events were observed and the levels of tumor necrosis factor-α（ TNF-α）, CD40L , P-selectin（Ps） were analyzed. Results：There were no difference at cardiac events in two groups. The levels of CD40L,Ps and TNF-α of two groups were similar at baseline （ P 〉 0. 05 ）, and that 30d after discharge in two groups were significantly lower than before PCI（ P 〈 0. 05 ）. The levels of TNF-α, CD40L and Ps in probucol group at 30d after discharge were similar with simvastatin group（P 〉 0. 05 ）. Conclusion： Probueol improve prognosis and inflammation after PCI in the patients with AMI.